AbbVie (ABBV) director Brett J. Hart awarded 1,118 restricted stock units in equity grant

Rhea-AI Filing Summary

Hart Brett J reported acquisition or exercise transactions in this Form 4 filing.

AbbVie Inc. director Brett J. Hart received an award of 1,118 shares of common stock in the form of restricted stock units. These units were granted at no cash cost to him and increase his direct holdings to 20,590 shares after the award.

The restricted stock units were granted under the AbbVie Amended and Restated 2013 Incentive Stock Program and will be settled one-for-one in AbbVie common stock. Settlement will occur on the earlier of his separation from service, death, or a change in control as defined in the program.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hart Brett J

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.01 par value	1,118	$0.00	--

Holdings After Transaction: Common Stock, $0.01 par value — 20,590 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 1,118 units Shares after transaction: 20,590 shares Par value: $0.01 per share

3 metrics

RSUs granted 1,118 units Restricted stock units awarded to director Brett J. Hart

Shares after transaction 20,590 shares Total AbbVie common shares directly held after award

Par value $0.01 per share Par value of AbbVie common stock

Key Terms

restricted stock units, Incentive Stock Program, change in control

3 terms

restricted stock units financial

"These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Incentive Stock Program financial

"awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program"

change in control financial

"death, or the occurrence of a change in control (as defined in the Program)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hart Brett J

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	05/08/2026		A		1,118(1)	A	$0	20,590	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

	/s/ T.O. Odutayo, Attorney-in-Fact for Brett J. Hart	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did AbbVie (ABBV) director Brett J. Hart report in this Form 4?

Brett J. Hart reported receiving 1,118 restricted stock units of AbbVie common stock. These units are a stock-based compensation award that increases his direct holdings to 20,590 shares after the grant, aligning his interests more closely with AbbVie shareholders over time.

How many AbbVie (ABBV) shares does Brett J. Hart hold after this grant?

After the award, Brett J. Hart holds 20,590 shares of AbbVie common stock directly. This figure includes the 1,118 restricted stock units granted, which are designed to convert into an equal number of AbbVie shares when settlement conditions are met in the future.

What type of equity award did Brett J. Hart receive from AbbVie (ABBV)?

Brett J. Hart received restricted stock units (RSUs) under the AbbVie Amended and Restated 2013 Incentive Stock Program. Each unit represents a right to receive one share of AbbVie common stock, subject to settlement upon specific events such as separation from service, death, or a change in control.

When will Brett J. Hart’s AbbVie (ABBV) restricted stock units be settled?

The restricted stock units will be paid in AbbVie common stock on the earlier of Brett J. Hart’s separation from service, his death, or a change in control. A change in control is defined in AbbVie’s Amended and Restated 2013 Incentive Stock Program governing the award.

Did Brett J. Hart pay cash for the AbbVie (ABBV) shares reported?

No, Brett J. Hart did not pay cash for these shares. The 1,118 units were granted at a reported price of $0.0000 per share as a stock-based compensation award under AbbVie’s incentive stock program, rather than through an open-market purchase transaction.